Expanded Access to Zidesamtinib for People with Advanced Solid Tumors

Full Title

Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients with Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors (EAP)

Purpose

Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.

Zidesamtinib acts directly on the ROS1 protein that contributes to cancer growth and survival. By blocking this protein, zidesamtinib may help slow or stop the growth of your cancer. Zidesamtinib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have NSCLC or other advanced solid tumor that keeps growing after treatment and has an ROS1 fusion.
• Have recovered from the serious side effects of prior anti-cancer therapies before taking zidesamtinib.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Alexander Drilon’s office at 646-608-3758.